Aprea Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $18.14 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aprea Therapeutics Inc had its IPO on 2019-10-03 under the ticker symbol APRE.
The company operates in the Healthcare sector and Biotechnology industry. Aprea Therapeutics Inc has a staff strength of 0 employees.
Shares of Aprea Therapeutics Inc opened at $5.1 at the start of the last trading session i.e. 2023-03-23.
The stocks traded within a range of $4.7 - $5.1, and closed at $4.75.
This is a -1.45% slip from the previous day's closing price.
A total volume of 7,753 shares were traded at the close of the day’s session.
In the last one week, shares of Aprea Therapeutics Inc have slipped by -9%.
Aprea Therapeutics Inc's Key Ratios
Aprea Therapeutics Inc has a market cap of $18.14 million, indicating a price to book ratio of 1.0351 and a price to sales ratio of 0.
In the last 12-months Aprea Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-37433524. The EBITDA ratio measures Aprea Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aprea Therapeutics Inc’s operating margin was 0% while its return on assets stood at -33.78% with a return of equity of -62.79%.
In Q3, Aprea Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Aprea Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-92.51 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aprea Therapeutics Inc’s profitability.
Aprea Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.1287. Its price to sales ratio in the trailing 12-months stood at 0.
Aprea Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $33.62 million
- Total Liabilities
- $4.00 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Aprea Therapeutics Inc ended 2023 with $33.62 million in total assets and $0 in total liabilities. Its intangible assets were valued at $33.62 million while shareholder equity stood at $26.63 million.
Aprea Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $4.00 million in other current liabilities, 52237.00 in common stock, $-291354263.00 in retained earnings and $0 in goodwill. Its cash balance stood at $33.11 million and cash and short-term investments were $33.11 million. The company’s total short-term debt was $110,551 while long-term debt stood at $0.
Aprea Therapeutics Inc’s total current assets stands at $33.47 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.14 million and inventory worth $0.
In 2023, Aprea Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Aprea Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aprea Therapeutics Inc stock is currently trading at $4.75 per share. It touched a 52-week high of $40.8 and a 52-week low of $40.8. Analysts tracking the stock have a 12-month average target price of $60.
Its 50-day moving average was $7.41 and 200-day moving average was $12.51 The short ratio stood at 3.52 indicating a short percent outstanding of 0%.
Around 1625.2% of the company’s stock are held by insiders while 546.2% are held by institutions.
Frequently Asked Questions About Aprea Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that target a critical pathway and various central targets in DNA damage response and cancer progression. Its lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor being developed for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.